RxDoctor Payments Data

Mustafa Safi, MD

Cornea and External Diseases Specialist · Eureka, CANPI 1518325455

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 60.9% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $453 and has fallen 73.4% since, to $120 in 2025. That places this record below the midpoint for cornea and external diseases specialist clinicians in CA, where the typical reported total is $4,024.

$591in general payments, 2019–2025

Across 10 payments — averaging $59.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$360
  • Sight Sciences, Inc.$111
  • Carl Zeiss Meditec USA, Inc.$39
  • Rxsight Inc$32
  • AbbVie$26
  • Bausch & Lomb Americas Inc.$23

What the payments were for

  • Food & beverage$591100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$591 in reported general payments places this provider in the 10th percentile of 50 cornea and external diseases specialist providers in California.

See all cornea and external diseases specialist providers in California

Medicare billing

Part B allowed, 2024
$172,984
Medicare patients
563
Services billed
1,395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate99$3,377
MoxifloxacinMoxifloxacin Hcl65$1,765
ValacyclovirValacyclovir Hcl14$1,038
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat18$238
Brimonidine Tartrate23$225
Latanoprost14$34

Paid to pharmacies, not to this prescriber.

Other cornea and external diseases specialist in Eureka

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →